These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 33796151)

  • 1. Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors.
    Gaucher L; Adda L; Séjourné A; Joachim C; Guillaume C; Poulet C; Liabeuf S; Gras-Champel V; Masmoudi K; Houessinon A; Bennis Y; Batteux B
    Ther Adv Med Oncol; 2021; 13():17588359211000591. PubMed ID: 33796151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
    Pinato DJ; Howlett S; Ottaviani D; Urus H; Patel A; Mineo T; Brock C; Power D; Hatcher O; Falconer A; Ingle M; Brown A; Gujral D; Partridge S; Sarwar N; Gonzalez M; Bendle M; Lewanski C; Newsom-Davis T; Allara E; Bower M
    JAMA Oncol; 2019 Dec; 5(12):1774-1778. PubMed ID: 31513236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the corticosteroid indication and administration route on overall survival and the tumor response after immune checkpoint inhibitor initiation.
    Gaucher L; Adda L; Séjourné A; Joachim C; Chaby G; Poulet C; Liabeuf S; Gras-Champel V; Masmoudi K; Moreira A; Bennis Y; Batteux B
    Ther Adv Med Oncol; 2021; 13():1758835921996656. PubMed ID: 33717227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
    Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C
    Front Immunol; 2021; 12():716317. PubMed ID: 34777340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of antibiotics on the anti-tumor efficacy of immune checkpoint inhibitor therapy.
    Nie F; Guo J; Pan J; Guo Z; Wang C; Yan J; Ma W
    Clin Transl Oncol; 2024 Jul; ():. PubMed ID: 39046682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts.
    Wu Q; Liu J; Wu S; Xie X
    Int Immunopharmacol; 2021 Mar; 92():107303. PubMed ID: 33465728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
    Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice.
    Pérez-Ruiz E; Jiménez-Castro J; Berciano-Guerrero MA; Valdivia J; Estalella-Mendoza S; Toscano F; Rodriguez de la Borbolla Artacho M; Garrido-Siles M; Martínez-Bautista MJ; Villatoro Roldan R; Rivas-Ruiz F; Nogales-Fernández E; Morales C; Pérez-Valderrama B; De la Cruz-Merino L; Rueda A
    Clin Transl Oncol; 2020 Oct; 22(10):1778-1785. PubMed ID: 32096143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients.
    Huang XZ; Gao P; Song YX; Xu Y; Sun JX; Chen XW; Zhao JH; Wang ZN
    Oncoimmunology; 2019; 8(12):e1665973. PubMed ID: 31741763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer.
    Iglesias-Santamaría A
    Clin Transl Oncol; 2020 Sep; 22(9):1481-1490. PubMed ID: 31919759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different classes of antibiotics exhibit disparate negative impacts on the therapeutic efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
    Qiu H; Ma QG; Chen XT; Wen X; Zhang N; Liu WM; Wang TT; Zhang LZ
    Am J Cancer Res; 2022; 12(7):3175-3184. PubMed ID: 35968357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors.
    Elkrief A; El Raichani L; Richard C; Messaoudene M; Belkaid W; Malo J; Belanger K; Miller W; Jamal R; Letarte N; Wong P; Routy B
    Oncoimmunology; 2019; 8(4):e1568812. PubMed ID: 30906663
    [No Abstract]   [Full Text] [Related]  

  • 16. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis.
    Abdelrahim M; Mamlouk O; Lin H; Lin J; Page V; Abdel-Wahab N; Swan J; Selamet U; Yee C; Diab A; Suki W; Abudayyeh A
    Oncoimmunology; 2021 May; 10(1):1927313. PubMed ID: 34104543
    [No Abstract]   [Full Text] [Related]  

  • 17. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: An up-to-date systematic review and meta-analysis.
    Yang M; Wang Y; Yuan M; Tao M; Kong C; Li H; Tong J; Zhu H; Yan X
    Int Immunopharmacol; 2020 Nov; 88():106876. PubMed ID: 32799113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia.
    Lu PH; Tsai TC; Chang JW; Deng ST; Cheng CY
    J Clin Pharm Ther; 2021 Apr; 46(2):408-414. PubMed ID: 33332621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.
    Chalabi M; Cardona A; Nagarkar DR; Dhawahir Scala A; Gandara DR; Rittmeyer A; Albert ML; Powles T; Kok M; Herrera FG;
    Ann Oncol; 2020 Apr; 31(4):525-531. PubMed ID: 32115349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
    Iyer PC; Cabanillas ME; Waguespack SG; Hu MI; Thosani S; Lavis VR; Busaidy NL; Subudhi SK; Diab A; Dadu R
    Thyroid; 2018 Oct; 28(10):1243-1251. PubMed ID: 30132401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.